Thus, the strategy of IR + highly specific IRAK1 inhibitor, whether alone or in combination with STING agonist, would be expected to sensitize tumor cells to IR while also allowing IL-1R/TLR-initiated immune attacks to proceed, which makes our studies focusing on the mechanism of IRAK1 in radioresistant tumors more valuable and promising. Here, STING1 is linked to neoplasm.